Clinical Trials

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06966700 2026-05-22

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

25 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

58 enrolled

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

15 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT07283692 2026-05-13

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

46 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07396324 2026-05-13

NEO-ITHRAN

55 enrolled

HR-positive/HER2-negative Breast Cancer

NCT06279364 2026-05-08

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

524 enrolled

Triple Negative Breast Neoplasms

NCT04771871 2026-05-07

TARMAC

42 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06845319 2026-05-06

NeoCARD

43 enrolled

Triple Negative Breast Neoplasms

NCT07220135 2026-05-06

NeoTHERa

100 enrolled

Breast Neoplasms

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06926868 2026-04-30

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07102381 2026-04-29

EmpowHER 208

125 enrolled

Breast Neoplasms

NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT07402473 2026-04-23

EUREKA

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT07074106 2026-04-01

DespaTIL

40 enrolled

Breast Neoplasms

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

544 enrolled

HER2-positive Breast Cancer

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

28 enrolled

Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

72 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Triple Negative Breast Neoplasms

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT07340398 2026-01-21

TAYLOR

200 enrolled

BreastGastrointestinalGynecologicThoracic

HER2-positive Early Breast Cancer

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase 1 Recruiting

495 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05256745 2025-12-24

RAGE

48 enrolled

Cancer Related Cognitive Decline

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

228 enrolled

Triple Negative Breast Neoplasms

NCT07178171 2025-11-24

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Phase 1 Recruiting

30 enrolled

Triple Negative Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

2,400 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04159142 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

414 enrolled

Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05315700 2025-08-05

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

350 enrolled

Breast Neoplasms

NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

812 enrolled

Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

180 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06747338 2025-04-24

Neo-Healer

520 enrolled